Last reviewed · How we verify
177Lu-DOTA-EB-TATE
Somatostatin receptor targeting
Somatostatin receptor targeting Used for Neuroendocrine tumors.
At a glance
| Generic name | 177Lu-DOTA-EB-TATE |
|---|---|
| Sponsor | Molecular Targeting Technologies, Inc. |
| Drug class | Somatostatin receptor targeting agent |
| Target | Somatostatin receptor |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 1 |
Mechanism of action
177Lu-DOTA-EB-TATE is a radioligand therapy that targets somatostatin receptors on neuroendocrine tumors.
Approved indications
- Neuroendocrine tumors
Common side effects
- Nausea
- Vomiting
- Diarrhea
Key clinical trials
- 177Lu-DOTA-EB-TATE in Adult Patients With Metastatic, Radioactive Iodine Non-Responsive Oncocytic (Hurthle-Cell) Thyroid Cancer (PHASE1, PHASE2)
- 177Lu-DOTA-EB-TATE in Adult Patients With Advanced, Well- Differentiated Neuroendocrine Tumors (PHASE1)
- Treatment Using 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors (PHASE1)
- 177Lu-DOTA-EB-TATE in Patients With Advanced Neuroendocrine Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- 177Lu-DOTA-EB-TATE CI brief — competitive landscape report
- 177Lu-DOTA-EB-TATE updates RSS · CI watch RSS
- Molecular Targeting Technologies, Inc. portfolio CI